Meta analysis of the clinical efficacy and adverse effects of Janus kinase inhibitors in the treatment of COVID-19
10.3760/cma.j.cn112866-20221014-00212
- VernacularTitle:Janus kinase抑制剂治疗新型冠状病毒肺炎的临床疗效和不良反应的Meta分析
- Author:
Wenyu ZHANG
1
;
Peilei CONG
;
Ke XV
;
Wenwen LEI
;
Xiaoshan ZHANG
;
Guizhen WU
Author Information
1. 中国疾病预防控制中心病毒病预防控制所，北京 102206
- Keywords:
Coronavirus Disease 2019;
Janus kinase inhibitor;
Adverse event;
Mortality
- From:
Chinese Journal of Experimental and Clinical Virology
2023;37(1):95-105
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To systematically evaluate the clinical efficacy and adverse effects of Janus kinase (JAK) inhibitors in the treatment of Coronavirus Disease 2019 (COVID-19).Methods:Meta-analysis of the clinical efficacy and adverse effects of Janus kinase inhibitors in the treatment of COVID-19 was performed on 19 papers that met the inclusion criteria, including tests for heterogeneity, relative risk ( RR), mean difference( MD) and publication bias. Results:For the Janus kinase inhibitor group compared with the control group in 19 studies, RR and 95% confidence interval (95% CI) were 0.52 (95% CI: 0.44-0.62), 0.45 (95% CI: 0.25-0.83), and 1.21 (95% CI: 1.03-1.43) for mortality, clinical deterioration and recovery rates, and the mean difference and 95% CI in recovery time was -0.96 (95% CI: -1.13--0.79); for adverse events (including serious adverse events, infections, embolism, deep vein thrombosis, pulmonary embolism, liver dysfunction, psychiatric disorders, renal and urinary disorders), only the P-value for serious adverse events was statistically significant, P=0.010, and the RR and 95% CI were 0.83 (95% CI: 0.72-0.97). Conclusions:JAK inhibitors help reduce mortality and improve clinical outcomes in patients hospitalized with COVID-19 without increasing the risk of adverse events.
